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Abstract 
Background/Objectives: Polyglandular autoimmune syndrome (PAS) is 
made up of a group of autoimmune disorders of the endocrine glands. The 
purpose of this study is to determine the types of PAS in a group of adults 
with thyroid diseases and diabetes mellitus (DM). 
Material and methods: The studied group was of 350 cases with an age 
between 17-79 years. The methods of investigation were represented by 
clinical, imaging, biochemical, hormonal and immunological parameters. 
Results: The prevalence of PAS in the study group was 17.14%, from which 
PAS I 0%, PAS II 3.14% (11.66% in the case of DM type 1 and 1.38% in the 
case of DM type 2, p < 0.001, X2 = 17.28) and PAS III 14% (71.66% in the 
case of DM type 1 vs. 2.06% in the case of DM type 2, p <0.001, X2 
=200.01). The type of PAS III was type III A for type 1 diabetes and type III 
C for type 2 diabetes. All the patients with PAS were middle-aged women. 
Conclusions: In our study group we find PAS at middle-aged women, the 
type II and III, which are prevailed in the group with type 1 diabetes, due to 
autoimmune origin.  
 
Keywords: Diabetes mellitus, thyroid disease, polyglandular autoimmune 
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Introduction 
The present study regards a topic of general interest, because it 
knows a few about the types and prevalence of polyglandular autoimmune 
syndrome (PAS) at adult’s patients with diabetes mellitus (DM).  
PAS is made up of a group of autoimmune disorders of the endocrine 
glands [Kahaly, 2009] and comprise endocrine, neurological, dermatological, 
gastroenterological and other diseases, which are in common autoimmune 
pathogenesis. Endocrine pathology may manifest as hypo-or hyper function 
of interested gland [Şerban, 2010]. 
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PAS syndromes include: PAS I, PAS II, PAS III, IPEX (XPID) 
syndrome (X-Link poliendocrinopathies, immune dysfunction, and diarrhea), 
non-organ-specific autoimmunity (such as systemic lupus erythematosus) + 
insulin anti-receptor antibodies, thymic tumors + autoimmune 
endocrinopathies, Graves disease + Hirata syndrome (anti-insulin 
autoantibodies), POEMS syndrome (polyneuropathy + organomegaly  + 
endocrinopathy + monoclonal serum protein + skin changes), congenital 
rubella, followed by the appearance of thyroiditis and type 1 diabetes ± other 
autoimmune diseases. Of these, the most common are PAS I, II and III 
[Şerban, 2010]. 
PAS type I (PAS I) is an autosomal recessive disorder caused by a 
mutation in the short arm of chromosome 21, characterized by the triad: 
muco-cutaneous candidiasis, hypoparathyroidism and Addison’s disease. 
The symptoms and signs appear in childhood; candidiasis is usually the first 
sign, followed usually by hypoparathyroidism and Addison disease 
[Aldasouqi et al, 2006, Myhre et al, 2001]. DM type 1 occurs in less than 4% 
of affected children, but increases to 12% by adults. Its incidence is 
<1/100000/year, being higher in communities where there is a high degree of 
consanguinity and F/M ratio is 0.8 - 2.4:1 [Sivarajah et al, 2006]. 
PAS type II (PAS II) is the most common endocrinopathy and is 
characterized by: Addison’s disease, Grave’s disease, autoimmune chronic 
thyroiditis (ACT), diabetes mellitus (DM) type 1, primary hypogonadism, 
myasthenia gravis and celiac disease. Most disorders are associated with the 
following HLA: A1, B8, DR3 (DQA1 * 0501, DQB1 * 0201) and DR4 
(DQA1 * 0301, DQB1 * 0302) [Sivarajah et al, 2006, Betterle et al, 2004].  
The most frequent clinical combination association is Addison 
disease and Hashimoto thyroiditis, while the least is Addison disease, 
Graves’s disease, and DM type 1 (Carpenter syndrome).  
PAS II occurs in adulthood, usually around the third and fourth 
decades of life. In United States, its frequency is 14-20 people per million 
and the female-to-male ratio is 3-4:1 [Obermayer-Straub et al, 1998].  
PAS type III (PAS III) is a PAS II syndrome, but without the 
adrenocortical involvement8. This syndrome is associated with diseases as: 
organ-specific autoimmune diseases (celiac disease, hypogonadism, and 
myasthenia gravis), organ-nonspecific or systemic autoimmune diseases 
(sarcoidosis, Sjogren syndrome, and rheumatoid arthritis), other diseases 
(gastric carcinoid tumor, malabsorption due to exocrine pancreatic 
deficiency), and may be classified into 3 subcategories: 
• PAS III A – ACT with immune-mediated DM  
• PAS III B - ACT with pernicious anemia 
• PAS III C - ACT with vitiligo and/or alopecia and/or other organ-
specific autoimmune disease 
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The exact international prevalence of PAS III is unknown. PAS III 
appears in middle-aged women but can occur in persons of any age; 
prevailed in females and no racial or ethnic differences in its frequency have 
reported [Aung et al, 2006].  
Autoimmune disease affecting a single endocrine gland is frequently 
followed by impairment of other glands, resulting in multiple endocrine 
failures. The identification of circulating organ-specific auto antibodies 
provided the earliest and strongest evidence for the autoimmune 
pathogenesis of polyglandular failure syndromes [Aung et al, 2006]. 
The diagnosis is established based on the symptoms and clinical 
manifestations of each case and it is recommended metabolic, hormonal and 
immunological investigations to confirm it [Şerban, 2010]. 
Treatment consists of hormone replacement for endocrine 
deficiencies, and it is specific for each disease in part. If it is instituted early, 
the patients have a good evolution and don’t develop complications [Şerban, 
2010]. 
The patients with PAS and their relatives should be monitored for 
life, because it is the risk for appearance for a new endocrinopathies. 
Monitoring is the periodic physical examination and specific tests, and 
counseling patients and their relatives, regarding early signs and symptoms 
of major components of the syndrome [Şerban, 2010]. 
The aims of the present study were to evaluate the prevalence of 
different types of PAS at adult’s patients with DM and thyroid diseases.   
 
Material and method 
Material 
Investigated population 
350 people with DM (307 F and 43 M), aged between 18 and 79 
years represented the studied group. Depending on glycemic balance, the 
group was divided into:  
- the group with DM type 1 – 60 (17.14%) (55 F and 5 M) 
- the group with DM type 2 – 290 (82.86%) (252 F and 38 M) (Fig.1) 
The subjects were investigated in the Clinic of Endocrinology, 
Timisoara, Romania, in the period January 2001 to December 2005.  
The study inclusion criteria were age over 18 years and the presence 
of DM and of thyroid disease.  
The study was approved by the local ethics committee. All patients 
provided oral informed consent.  
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Methods of investigation  
The methods of investigation were represented by clinical data - case 
history, current status, imagistic- thyroid ultrasound, biochemical - for 
glycemic balance: fasting blood glucose, glycosylated hemoglobin, 
investigation of the thyroid gland: TSH, FT4, FT3, thyroid antibodies, 
investigation of the adrenal gland: cortisol, ACTH, 21-hydroxylase 
antibodies, gonadotropins: FSH, LH and appropriate sex hormones 
(testosterone, estradiol), investigation of celiac disease: ant tissue 
transglutaminase antibodies, investigation of pernicious anemia: complete 
blood count with mean cell volume and vitamin B12 levels, parietal cell and 
anti-intrinsic factor antibodies.  
Determination of plasma glucose was performed by enzyme 
technique with glucosooxidasis. Normal values: 70 - 110 mg%; DM - values 
equal or over 126 mg%. 
Determination of HbA1c was achieved through the DiaStat for 
measuring HbA1c reported to the total HbA.  
The TSH level in plasma, the free fraction of triiodotironin (FT3), 
and the plasma free fraction of thyroxin (FT4) were performed with 
ARCHITECT quantitative method, which is an immunological method, 
Chemilumnescent Microparticle Immunoassay (CMIA).  Normal values: 
TSH = 0.465-4.68 Miu/ml, FT3 = 3.69 -10.4 pmol/l, FT4 = 10-28.2 pmol/l.  
The level of cortisol was performed by IMMULITE / IMMULITE 
1000 technique, an imunometric method, of chemiluminescent, Immuno 
Chemilumino Enzymometric assay (ICEM). Normal value: a.m. 5-25 
microgram/dl.  
FSH level was measured quantitatively by the ARCHITECT method; 
a CMIA. Reference values are shown in Table 1. 
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Table 1. The reference values for FSH 
Population field mIU/ml 
Women: 
- Follicular phase 
- Ovulating phase 
- Luteal phase 
- Postmenopausal 
 
3.35 – 21.63 
4.97 – 20.82 
1.11 – 13.99 
2.58 – 150.53 
Men 1.37 – 13.58 
 
Testosterone was determinate by ELISA method. References values: 
Adults: men: 0.019-0.145 nmol/L; women in fertile period: <0.014 nmol/L; 
pills: 0.001-0.0069 nmol/L; postmenopausal: 0.0003-0.0058 nmol/L. 
Estradiol was determinate by immunochemical with 
electrochemiluminiscent detection method (ECLIA). References values are 
shown in Table 2. 
Table 2. The reference values for estradiol 
Population field pg/ml 
Women: 
- Follicular phase 
- Ovulating phase 
- Luteal phase 
- Postmenopausal 
 
35 -169 
49 - 427 
53 -191 
18 -110 
Men 25 -107 
 
To determine serum levels of antiperoxidase (antiTP) and 
antithyroglobulin (antiTg) antibodies it was used the kit AxSYM antiTPO, 
respectively the kit AxSYM antiTg, and an immunological method 
(Microparticle Enzyme Immunoassay) (MEIA). Normal values: antiTPO 
antibodies <35 IU/ml, antiTg antibodies <55 IU/ml.  
To determine 21-hydroxylase (anti 21-OH antibodies) antibodies 
level it was used the radioimunodetermination method combined with a 
technique of imunoprecipitation. Normal range: <1 IU/ml  
ACTH was determinate by immunoassay with chemiluminescent 
detection method.  
Antitissue transglutaminase antibodies were determinate by ELISA 
method. References values: IgA, IgG : <10 U/mL: negative;  ≥10 U/mL: 
positive. 
 Vitamin B12 levels were determinate by immunochemical with 
ECLIA method. References values: 191-663 pmol/L (for european 
population). 
Parietal cell antibodies were determinate by indirect 
immunofluorescence. References values: negative. 
Anti-intrinsic factor antibodies were determinate by ELISA method.  
References values: < 6 U/mL: negative. 
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Determination of complete blood count was achieved with electric 
impedance method. Normal values:  erythrocytes = 4-5.5 mil/mm3 (men: 4.9 
± 0.7 mil/mm3, women: 4.3 ± 0.6 mil/mm3), leucocytes = 5000 – 9000 
mil/mm3, plateled = 150000 – 350 000/mm3, hematocrit: men 45 ± 7%, 
women 42 ± 5%, hemoglobin: men: 15 ± 2 g/dl, women: 14 ± 2 g/dl.  
Constants and red cell indices are calculated automatically, 
depending on the values of hemoglobin, hematocrit and red blood cell count. 
Normal values: mean corpuscular volume = 80-100 fl, mean corpuscular 
hemoglobin concentration = 32-36 g Hb/100 ml erythrocytes, mean 
corpuscular hemoglobin = 27-32 pg.  
Thyroid ultrasound was performed in all cases and allowed us to 
measure thyroid volume, thyroid study and the changes in parenchyma’s 
density.  
Normal thyroid parenchyma presents an increased density, uniform, 
while inflammatory processes and autoimmune pathology appears hypo 
dens.  
ACT disorder appears with a hypoecogenity of the parenchyma and 
normal or increased thyroid volume.  
 
Statistical analysis 
For statistical analysis we used Microsoft Excel and POP Tools from 
Microsoft Office 2003 and EPI 2000 program. To measure the quantitative 
variables were determined media and standard deviation, and to assess the 
gender differences and other differences we used the unpaired t test and 
ANOVA test, considering statistically significant a p < 0.05.  
 
Results and discussion 
In the group of adults 17.14% had DM type 1 and 82.86% had DM 
type 2.  
The prevalence of PAS was 17.14%, from which PAS I 0%, PAS II 
3.14% and PAS III 14% (Table 3). 
Table 3. Prevalence of PAS in the study group 
Types of PAS Subject group No. % 
PAS I 0 0 % 
PAS II 11 3.14 % 
PAS III 49 14% 
 
We don’t find PAS I in our study group. 
The prevalence of PAS II was 3.14 % (11.66% for DM type 1 and 
1.38% for DM type 2, p = 0.00003, X2 = 17.28) (Table 4). 
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Table 4. The prevalence and characteristic of PAS II in the study group 
 DM type 1 DM type 2 
Associations DM type 1 + ACT + asimtomatic Addison disease 
DM type 2 + ACT + Addison 
disease 
Prevalence 11.66% 1.38% 
Gender female female 
Family history of thyroid 
disease none none 
Actual age (years) 44.28±23.57 61.75±7.32 
Onset age of thyroid disease 
(years) 37.33 ± 2.42 60.75±8.38 
Onset age of DM (years) 14.83 ± 10.88 59.75 ± 7.22 
DM duration (years) 24.83 ± 8.75 2 ± 0.81 
Thyroid disease duration 
(years) 2.33 ± 0.51 1 ± 1.41 
BMI (kg/m2) 25.72 ± 2.65 32.75 ± 4.42 
Glycemia (mg%) 268.83 ± 139.73 94.75 ± 36.79 
HbA1c (%) 12.93 ± 5.4 6.22 ± 2.11 
DM clinically manifest asymtomatic 
DM treatment insulin in different therapeutic schemes diet 
 
In 2 cases, the first disease was DM type 1; follow by ACT after 
2±0.5 years. In 5 cases, the first disease was ACT; follow by DM type 1 after 
27.8 ± 23.13 years.  
For appreciation association of Addison disease, were determinate 
plasma cortisol and 21-OH antibodies. The 21-OH values were significally 
higher in 7 cases, all theses were clinically asymptomatic.  
In the case of DM type 2 all the 4 cases with Addison diseases were 
symptomatic; the diagnosis was early, base on clinical symptoms. In the case 
of association between Addison disease and ACT, the first imunophathy was 
Addison disease; follow after 16 years by ACT.  
The prevalence of PAS III was 14% (100% F and 0% M, p<0.001, 
X2 =52.69).  
PAS III prevalence in DM type 1 was 71.66% (100% F and 0% M, 
p<0.001, X2 = 67.01) and 2.06% in DM type 2 (100% F and 0 % M, p = 
0.01, X2 = 6.06) (71.66% vs. 2.06%, p <0.001, X2 =200.01).  
In the case of DM type 1 we have PAS III A, and in the case of DM 
type 2 only PAS III C. (Fig. 2).  
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In the group with DM type 1 the main endocrine immune 
combinations were represented by DM type 1 with ACT. Other endocrine 
immune associations were represented by autoimmune ovarian insufficiency 
(AOI) and the no endocrine disorders as vitiligo, alopecia, and Biermer 
anemia (Table 5).  
Table 5. Prevalence of PAS III in the study group 
Associations Subject group No. % 
DM type 1 60  
DM type 1 + ACT 31 51.66% 
DM type 1 + ACT + decalvant pelada 2 3.33% 
DM type 1 + ACT + vitiligo 3 5% 
DM type 1 + ACT + autoimmune ovarian failure 6 10% 
DM type 1 + ACT + vitiligo + Biermer anemia 1 1.66% 
DM type 2 290  
DM type 2 + ACT + vitiligo 6 2.06% 
 
In the group of adults with DM type 1 the first imunopathy was DM 
type 1, present in 24 of cases and was associated with ACT in all 24 cases. In 
2 cases, thyroid disorder and DM type 1 were detected at the same time.  In 
17 cases thyroid disorder preceded the DM type 1. 
For detect AOI was determine the levels of FSH, increased > 25 IU/l 
in 6 cases. Primary ovarian insufficiency (early menopause) usually occurs 
before the age of 40 years (in the absence of iatrogenic causes) and its 
clinical signs are secondary amenorrhea and hypergonadotropism with 
hypoestrogenemia.  
AOI is usually associated with other autoimmune pathology such as 
DM type 1, Addison’s disease, ACT, vitiligo, etc.; its diagnosis is difficult 
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and it is usually based on the exclusion of other possible causes of primary 
ovarian insufficiency and the notice of autoimmune etiology [Aung et al, 
2006].  
Also estrogen therapy in AOI may increase the risk of cardiovascular 
disease [Kalantaridou et al, 1999].  
In 4 cases was associated vitiligo and in 2 cases decalvant pelada, 
which occurred before the onset of endocrine immunopathys. In one case 
was associated more than one nonendocrine autoimmune disorder 
respectively Biermer anemia and vitiligo. 
In adults, the average time between the onset of type 1 DM and ACT 
was 22.29 ± 12.42 years.  
In 17 cases the first immunopathy was ACT, followed by DM type 1 
after 2.47 ± 1.94 years.  
The characteristic and prevalence of PAS III in DM type 1 and 2 
group are show in Table 6.  
Table 6. The characteristic of PAS III in the study group 
 DM type 1 DM type 2 
Prevalence 71.66% 2.06% 
Gender female female 
Family history of thyroid 
disease none none 
Actual age (years) 43 ± 18.95 55 ± 14.14 
Onset age of thyroid 
disease (years) 30.46 ± 22.94 53.5 ± 12.02 
Onset age of DM (years) 31.84 ± 25.21 57 ± 4.94 
DM duration (years) 16.25 ± 13.71 0 
Thyroid disease duration 
(years) 4.56 ± 4.17 25.6 ± 24.15 
BMI (kg/m2) 25.19 ± 3.51 28.24 ± 7.66 
Glycemia (mg%) 196.81 ± 89.19 99 ± 18 mg% 
HbA1c (%) 10.94 ± 3.85 5.06 ± 0.69 
DM clinically manifest asymtomatic 
DM treatment insulin in different therapeutic schemes diet 
 
Prevalence of ACT in DM type 2 was 26.55% (77 patients, 69 F and 
8 M). In adults with DM type 2 PAS type III was found in 6 (2.06%) cases, 
of which all have ACT + vitiligo. The first disease was vitiligo follow by 
ACT after 2-5 years. DM type 2 appears after ACT, at 5-10 years, possible 
because of replacement therapy for thyroid disease.  
Also in these cases it is useful to determinate the antibodies for 
diabetes because these patients may have latent autoimmune diabetes 
(LADA) and in time requires insulin.  
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In general, in the first stage of PAS, antibodies levels are elevated. In 
the second stage the disease is sub clinical and in the third stage becomes 
clinically manifested.  
By ACT, 24 cases were euthyroid and 96 cases hypothyroid (76 
clinical cases and 20 cases sub clinical). 24 cases did not require treatment; 
the remaining had substitution treatment with thyroid hormones. AntiTPO 
antibodies were present in 27 cases of ACT and DM type 1, the remaining 
cases presenting insignificant values.  
 
Discussion 
PAS I comprises candidiasis, hypoparathyroidism, and adrenal 
failure [Alimohammadi et al, 2008] (a case without mucocutaneous 
candidiasis has been reported in an adolescent [Bhansali et al, 2003]).  
In North America studies about PAS I was published by Neufeld and 
colleagues in 1981 and by Heino and coauthors in 1999 [Neufeld et al, 1981, 
Heino et al, 1999]. In the latter report, 16 patients were described, including 
13 white patients, 1 Hispanic individual, 1 Middle Eastern patient, and 1 
Asian person.  
In Europe, PAS I cluster in certain homogeneous ethnic populations 
due to consanguineous marriages. It is more common in Finland (1 case per 
25,000 [Bjorses et al, 2000]), in Sardinians (1 case per 14,400) and in Iranian 
Jews (1 case per 9,000) [Rosatelli et al, 1998, Zlotogora et al, 1992] and is 
less frequent in northern Italy, northern Britain, Norway, and Germany.  
It usually occurs in children aged 3-5 years or in early adolescence 
(always in the early part of the third decade of life); F/M ratio is 0.8 - 2.4:1 
[Dittmar et al, 2003]. The genetic mode of transmission is autosomal 
recessive, although an X-linked inheritance fashion in a female was report 
from Italy, by Iannello and colleagues [Iannello et al, 1997].  
Because PAS I is very rare and occurs in children, we don’t find this 
syndrome in our study (one of the criteria was the age over 18 years). 
PAS II is characterized by the obligatory occurrence of autoimmune 
Addison disease in combination with ACT and/or type 1 diabetes, but can 
comprise also primary hypogonadism, myasthenia gravis, and celiac disease. 
The prevalence of PAS II is 1:20 000 [Cooper e al, 2003] and appears 
usually in women (F/M = 1:3) [Fo¨rster et al, 1999]. It occurs at ages 20–60 
years, mostly in the third or fourth decade [Ten et al, 2000], and it is 
common for multiple generations to be affected by one or more component 
of the disease [Neufeld et al, 1980]. While there is some correlation between 
the ages of onset of one PAS illness with another, many years may separate 
the onset of different diseases [Fo¨rster et al, 1999]. All the disorders 
resulting in tissue destruction appear to have a prolonged phase of cellular 
loss preceding overt autoimmune glandular disease [Kahaly, 2009]. 
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In a study perform by Betterle et al, DM was found in 57–63% of 
cases, while Addison's disease preceded DM in 23–35% and the two diseases 
appeared to be simultaneous in 8–10% of cases; in 4% of  patients the 
sequence of the diseases was not specified. Many patients with this 
association died within one year by the time of the clinical diagnosis 
[Betterle et al, 2004]. 
In our study, the prevalence of PAS II in the study group was 3.14 % 
(11.66% for DM type 1 and 1.38% for DM type 2, p = 0.00003, X2 = 17.28). 
All patients were middle – aged women, so concordant with literature data.  
The low frequency of PAS II in our study can be due by the low 
number of patients with DM type 1 and thyroid disease and because many 
patients with Addison disease died at a short time after diagnosis, before to 
be investigate for DM type 1.  
In the case of PAS III, the exact international prevalence and in the 
United States is unknown. No racial or ethnic difference in frequency of PAS 
III has been reported. It is more common in females than in males and 
typically is observed in middle-aged women but can occur in persons of any 
age. 
The prevalence of PAS III in the study group was 14% (71.66% for 
DM type 1 and 2.06% for DM type 2, p <0.001, X2 =200.01). All patients 
were middle-aged women, so concordant with literature data.  
Hunger –Batterfeld et al studied the prevalence of PAS in 139 
patients with DM type 1 and found in 24.5% ACT, in 4.3% Graves' disease, 
in 1.4% Addison's disease, in 1.4% celiac disease, in 7.2% pernicious 
anemia, in 0.7% hypophysitis and in 0.7% hypogonadism [Hunger-Battefeld 
et al, 2009]. 
In our study, in some cases, one of the disease was asymptomatic, 
characterized by increased of specific antibodies.  
In DM type 1 is ideal to determine the presence of antibodies because 
they may be present in subjects without clinical symptoms. If their levels are 
raised, it is good to monitor annual the TSH level and if it is normal it is 
recommended to doze antithyroid antibodies by intervals of 2-3 years 
[Eisenbarth et al, 2004, Tunbridge et al, 2000].  
Also, if the disease is autoimmune, the patient should be investigated 
for other autoimmune associations of endocrine or nonendocrine nature.  
If DM type 2 is present it is recommended to evaluate TSH levels, 
and if it is normal, to repeat this evaluation every 5 years.  
If pre-existing thyroid pathology is present it is recommended to 
evaluate plasma glucose levels annually.  
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Conclusion 
In our study group we find PAS at middle-aged women, the type II 
and III, which are prevailed in the group with DM type 1, due to autoimmune 
origin.  
Regarding PAS type III, we encountered type III A in DM type 1and 
type III C in DM type 2 (this may be LADA).  
Because one of the disease was asymptomatic, characterized by 
increased of specific antibodies, we must investigate this for another possible 
autoimmune disease.  
Active detection of patients with PAS allows an early diagnosis and 
an appropriate treatment, to prevent complications, which prolongs the life of 
patients and improve its quality. 
The PAS classification is not final. This may change over time, with 
the onset of new endocrine disorders or associations with new autoimmune 
determination.  
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